Jacobus Pharmaceutical freely gives its experimental drug to patients with a rare disease. Now a rival wants FDA approval to sell its own version — and expects to charge at least $37,500 per year.
Get more stuff like this
in your inbox
Subscribe to our mailing list and get interesting stuff and updates to your email inbox.
Thank you for subscribing.
Something went wrong.